Hip Arthritis Associated With AS Efficacy and Safety of Early Treatment With Infliximab [Remicade].
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 14 Mar 2018
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms HACER
- Sponsors Merck & Co; Merck Sharp & Dohme
- 24 Jan 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Jan 2011 Planned end date changed from 1 Sep 2011 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 17 Aug 2010 Trial location (Spain) added as reported by ClinicalTrials.gov.